Search
Novo Nordisk Plummets 9% in U.S. Pre-Market Trading Amid Downgraded 2025 Outlook
2025-07-29 /
Read about 0 minute
Author：小编
Novo Nordisk experienced a 9% drop in U.S. pre-market trading following the company's decision to revise downwards its sales growth projections for 2025. The revised forecast now anticipates full-year sales growth to range between 8% and 14% at constant exchange rates, marking a significant decrease from the previously anticipated range of 13% to 21%. This adjustment stems from lower growth expectations for Wegovy in the American obesity market, slower growth for Ozempic in the U.S. GLP-1 diabetes market, and Wegovy's underperformance in achieving market penetration targets in certain international obesity (IO) markets.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
